Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Agenus published Phase 1b data for its botensilimab and balstilimab combination in patients with hepatocellular carcinoma who progressed after prior immunotherapy. The study of 19 heavily pretreated patients showed a 17% objective response rate and a median overall survival of 12.3 months, which compares favorably to historical controls in this difficult-to-treat population.
Key figures
- Drug Name
- botensilimab (BOT) and balstilimab (BAL)
- Phase Of Trial
- Phase 1b
- Orrr
- 17%
- Median os
- 12.3 months
- Median pfs
- 4.4 months
- Patient count
- 19
- Clinical benefit rate
- 50%
- Grade 3 adverse events
- 37%
- Efficacy evaluable count
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.